Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Prognosis In Malignant Mesothelioma Related To MIB 1 Proliferation Index And Histological Subtype.

T. Beer, R. Buchanan, A. W. Matthews, R. Stradling, N. Pullinger, R. Pethybridge
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The aims of this study were to evaluate the use of the proliferation marker MIB 1 and histological subtype as indicators of prognosis in malignant mesothelioma. Sections from 41 cases of malignant mesothelioma were histologically subtyped on hematoxylin and eosin sections and stained immunohistochemically for the proliferation marker MIB 1. A proliferation index was derived and the results compared with patient survival data. A statistically significant difference was found between the survival of patients having a low and high MIB 1 index (P < .001). Patients with tumors having a low MIB 1 index lived significantly longer than those with a high MIB 1 index. Patients with the spindle cell histological subtype of malignant mesothelioma had significantly shorter survival times than those with the epithelioid or mixed tumors (P < .01). The MIB 1 proliferation index and histological tumor subtype are useful markers of prognosis in malignant mesothelioma.
This paper references
10.1136/jcp.45.4.295
Desmoplastic malignant mesothelioma: a review of 17 cases.
G. Wilson (1992)
10.5694/J.1326-5377.1989.TB136324.X
Nine‐year survival in a case of untreated peritoneal mesothelioma
P. Norman (1989)
[Prognostic factors in diffuse malignant mesothelioma of the pleura].
J. Schildge (1989)
10.1007/978-3-642-57927-1
Histological Typing of Soft Tissue Tumours
D. Weiss (1994)
10.1111/j.1365-2559.1993.tb00174.x
The relevance of antibody concentration to the immunohistological quantification of cell proliferation‐associated antigens
D. McCormick (1993)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
[Epidemiology and etiology of mesothelioma].
J. Viallat (1990)
10.1002/PATH.1711720304
Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA)
M. Ramael (1994)
10.1136/jcp.49.11.926
MIB-1 proliferative activity in invasive breast cancer measured by image analysis.
P. Querzoli (1996)
[Diagnosis and prognosis of malignant mesothelioma].
C. Boutin (1990)
10.2307/2344317
Asymptotically Efficient Rank Invariant Test Procedures
R. Peto (1972)
Thymidine labeling index and Ki-67 growth fraction in lesions of the breast.
O. Kamel (1989)
10.1136/thx.44.6.496
Malignant pleural mesothelioma in western Glasgow 1980-6.
G. Hulks (1989)
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
J. Gerdes (1984)
10.1002/PATH.1711700102
In situ end‐labelling detects DNA strand breaks in apoptosis and other physiological and pathological states
B. Ansari (1993)
10.1002/PATH.1711590413
Soft tissue tumours
C. D. Fletcher (1989)
10.1378/CHEST.103.4_SUPPLEMENT.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.1378/CHEST.109.1.109
Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
L. Johansson (1996)
10.1016/1010-7940(91)90142-7
Diagnostic and therapeutic strategy in malignant pleural mesothelioma.
D. Branscheid (1991)
10.1002/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G
Prognostic factors of malignant mesothelioma of the pleura.
A. Anand (1994)
10.1111/j.1365-2559.1990.tb00788.x
Monoclonal antibody Ki‐67: its use in histopathology
D. C. Brown (1990)
10.1038/bjc.1995.30
Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.
S. Pinder (1995)
10.1136/bmj.313.7057.615
ABC OF Work Related Disorders: OCCUPATIONAL CANCERS
C. Veys (1996)
10.1111/j.1365-2559.1993.tb00135.x
Detection of the Ki‐67 antigen in fixed and wax‐embedded sections with the monoclonal antibody MIB1
D. McCormick (1993)
[Malignant pleural mesotheliomas].
S. Mercurio (1998)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1111/j.1365-2559.1992.tb00454.x
The complexities of proliferating cell nuclear antigen
D. McCormick (1992)
10.1016/S0344-0338(11)81020-4
Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.
R. Walz (1990)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1136/jcp.44.8.655
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma.
S. Jain (1991)
10.1016/1010-7940(89)90056-0
The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.
R. Achatzy (1989)



This paper is referenced by
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL
Namballa Usharani (2014)
10.1097/00129039-200009000-00002
Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia.
H. Saleh (2000)
10.1136/thx.2003.008912
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
A. Baldi (2004)
10.1046/j.1365-2559.2003.01628.x
Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma
J. Sington (2003)
10.1007/3-540-27329-8_7
Prognostische Faktoren und Evaluationskriterien
J. A. Burgers (2005)
10.1097/JTO.0000000000000055
PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy
B. Bitanihirwe (2014)
Angiogenesis, cyclooxygenase-2 and matrix metalloproteinases in malignant mesothelioma
J. Edwards (2003)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
10.1002/1097-0215(20001001)88:1<37::AID-IJC6>3.0.CO;2-3
Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma
K. Kahlos (2000)
10.1007/978-1-4615-1589-0_13
Malignant pleural mesothelioma.
L. Ho (2001)
MALIGNANT PLEURAL MESOTHELIOMA TREATED BY EXTRAPLEURAL PNEUMONECTOMY-A CASE REPORT
Mohit Sharma (2016)
10.1007/s004280100529
Alterations of E-cadherin, α-catenin and β-catenin expression in neuroendocrine tumors of the gastrointestinal tract
C. Li (2002)
10.1378/CHEST.06-0655
A localized pleural based mass with intense uptake on positron emission tomography scan.
A. Khan (2007)
10.1111/j.1365-2559.2004.01844.x
Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease
P. Lumb (2004)
10.7556/JAOA.2006.106.12.699
Malignant mesothelioma: a case presentation and review.
Timothy J. Barreiro (2006)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1097/00022744-200009000-00002
Immunohistochemical Expression of bcl-2 and p53 Oncoproteins: Correlation with Ki67 Proliferation Index and Prognostic Histopathologic Parameters in Colorectal Neoplasia
H. Saleh (2000)
Summary. Cyclooxygenases catalyze the rate limiting step in the production of prostanoids. Accumulating data demonstrate that overexpression of these enzymes, and in particular of cyclooxygenases-2, promotes multiple events involved in tumorigenesis; in addition, numerous studies show that inhibitio
(2005)
10.1038/modpathol.2011.146
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
Kyuichi Kadota (2012)
10.1097/00001622-200303000-00002
Predictive and prognostic factors in malignant pleural mesothelioma
P. Baas (2003)
10.1002/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G
p27kip1 immunoreactivity correlates with long‐term survival in pleural malignant mesothelioma
M. Bongiovanni (2001)
The expression and possible role of manganese superoxide dismutase in malignant pleural mesothelioma
K. Kahlos (1999)
10.4081/RT.2010.E46
Sarcomatous malignant peritoneal mesothelioma with large bowel involvement
Tomoaki Kaneko (2010)
Advances in diagnosis and treatment of malignant mesothelioma
J.P.J.J. Hegmans (2006)
10.1016/S1092-9134(00)90036-4
Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma.
T. Beer (2000)
10.1080/00313020500456017
Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations
Çağlar Çakır (2006)
10.1155/2004/285681
Diagnostic and Prognostic Value Of Ki67 Proliferation Fraction in Serous Effusions
A. Schönherr (2004)
Review Cox and mesothelioma: an overview
I. Cardillo (2005)
10.14260/JEMDS/2014/2699
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA
Gorantla Sambasivarao (2014)
10.1155/2016/6898526
Posterior Mediastinal Adenomatoid Tumor: A Case Report and Review of the Literature
Vishwas Parekh (2016)
10.1111/j.1365-2559.2011.04108.x
High Wilms’ tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma
A. Scattone (2012)
10.1007/978-3-642-56297-6_2
Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren
K. Müller (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar